GERMANTOWN, Md., June 2, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today the appointment of Olivier R. Jarry, M.B.A, as Senior Vice President, Consumer Sector. Mr. Jarry will lead the expansion of Intrexon's programs employing novel biologically-based solutions in products and applications for consumer markets.
Mr. Jarry brings to Intrexon over 30 years of experience in leading global life sciences and consumer health executive roles. Most recently Mr. Jarry founded and served as Managing Partner of Imagiance LLC, a strategic, management and transaction advisory firm focusing on optimizing portfolio value and integrated care for biotechnology and medical technology companies. Prior to Imagiance, he was Head of Strategy, Operations, Market Access in Emerging Markets at Bristol-Myers Squibb, where he led commercial operations for a $1 billion dollar division. Mr. Jarry also held executive roles at Bayer Healthcare as the Global Business Unit Head for Bayer Diabetes Care, coordinating the successful launch of five new products, and at Novartis, Danone, and Accenture. He holds an M.B.A. from the TRIUM Global Executive Program.
Intrexon's Chairman and Chief Executive Officer Randal J. Kirk commented, "Olivier's creative strategic outlook combined with extensive global experience in large, multi-national companies will help Intrexon capitalize on our platforms to build consumer-centric solutions and products. His expertise in implementing approaches for sustainable and profitable growth in global consumer markets will strengthen our outreach and ability to drive toward new consumer programs both in the United States and abroad."
Mr. Jarry added, "I am thrilled to join this innovative organization at a time when the promise of synthetic biology and its applications are emerging in the consumer market. I am very confident that we will offer consumers many new products that they will want and love, enhancing their everyday lives."
About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet. The Company's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com.
Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.
For more information contact:
Marie Rossi, Ph.D.
Senior Manager, Technical Communications
Tel: +1 (301) 556-9850
Vice President, Investor Relations
Tel: +1 (561) 410-7052
SOURCE Intrexon Corporation